肠道微生物组和代谢组对炎症性肠病生物疗法反应的预测价值有限

Femke M. Prins, Iwan J. Hidding, Marjolein A.Y. Klaassen, Valerie Collij, Johannes P.D. Schultheiss, Werna T.C. Uniken Venema, Amber Bangma, Jurne B. Aardema, Bernadien H. Jansen, Wout G.N. Mares, Ben J.M. Witteman, Eleonora A.M. Festen, Gerard Dijkstra, Marijn C. Visschedijk, Herma H. Fidder, Arnau Vich Vila, Bas Oldenburg, Ranko Gacesa, Rinse K. Weersma
{"title":"肠道微生物组和代谢组对炎症性肠病生物疗法反应的预测价值有限","authors":"Femke M. Prins, Iwan J. Hidding, Marjolein A.Y. Klaassen, Valerie Collij, Johannes P.D. Schultheiss, Werna T.C. Uniken Venema, Amber Bangma, Jurne B. Aardema, Bernadien H. Jansen, Wout G.N. Mares, Ben J.M. Witteman, Eleonora A.M. Festen, Gerard Dijkstra, Marijn C. Visschedijk, Herma H. Fidder, Arnau Vich Vila, Bas Oldenburg, Ranko Gacesa, Rinse K. Weersma","doi":"10.1101/2024.05.10.24307195","DOIUrl":null,"url":null,"abstract":"<strong>Introduction</strong> The complexity of Inflammatory Bowel Diseases (IBD) presents challenges for the management of these diseases. Predicting treatment outcomes remains difficult, leading to suboptimal outcomes and high costs. Emerging evidence suggests the potential of the gut microbiome in predicting response to biologic treatments. In this prospective study we aimed to predict treatment response to vedolizumab and ustekinumab in 79 IBD patients by integrating clinical data, gut microbiome profiles and fecal metabolites and validating these findings in a replication cohort of 47 IBD patients.","PeriodicalId":501258,"journal":{"name":"medRxiv - Gastroenterology","volume":"1 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-05-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Limited predictive value of the gut microbiome and metabolome for response to biological therapy in inflammatory bowel disease\",\"authors\":\"Femke M. Prins, Iwan J. Hidding, Marjolein A.Y. Klaassen, Valerie Collij, Johannes P.D. Schultheiss, Werna T.C. Uniken Venema, Amber Bangma, Jurne B. Aardema, Bernadien H. Jansen, Wout G.N. Mares, Ben J.M. Witteman, Eleonora A.M. Festen, Gerard Dijkstra, Marijn C. Visschedijk, Herma H. Fidder, Arnau Vich Vila, Bas Oldenburg, Ranko Gacesa, Rinse K. Weersma\",\"doi\":\"10.1101/2024.05.10.24307195\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<strong>Introduction</strong> The complexity of Inflammatory Bowel Diseases (IBD) presents challenges for the management of these diseases. Predicting treatment outcomes remains difficult, leading to suboptimal outcomes and high costs. Emerging evidence suggests the potential of the gut microbiome in predicting response to biologic treatments. In this prospective study we aimed to predict treatment response to vedolizumab and ustekinumab in 79 IBD patients by integrating clinical data, gut microbiome profiles and fecal metabolites and validating these findings in a replication cohort of 47 IBD patients.\",\"PeriodicalId\":501258,\"journal\":{\"name\":\"medRxiv - Gastroenterology\",\"volume\":\"1 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-05-10\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"medRxiv - Gastroenterology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1101/2024.05.10.24307195\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"medRxiv - Gastroenterology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1101/2024.05.10.24307195","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

导言 炎症性肠病(IBD)的复杂性给这些疾病的治疗带来了挑战。预测治疗结果仍然困难重重,导致治疗效果不理想和高昂的费用。新的证据表明,肠道微生物组在预测对生物治疗的反应方面具有潜力。在这项前瞻性研究中,我们旨在通过整合临床数据、肠道微生物组图谱和粪便代谢物来预测 79 例 IBD 患者对维多利珠单抗和乌司替尼的治疗反应,并在 47 例 IBD 患者的复制队列中验证这些发现。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Limited predictive value of the gut microbiome and metabolome for response to biological therapy in inflammatory bowel disease
Introduction The complexity of Inflammatory Bowel Diseases (IBD) presents challenges for the management of these diseases. Predicting treatment outcomes remains difficult, leading to suboptimal outcomes and high costs. Emerging evidence suggests the potential of the gut microbiome in predicting response to biologic treatments. In this prospective study we aimed to predict treatment response to vedolizumab and ustekinumab in 79 IBD patients by integrating clinical data, gut microbiome profiles and fecal metabolites and validating these findings in a replication cohort of 47 IBD patients.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信